BPC-157

In plain language

BPC-157 is a small, lab-made peptide: a short chain of 15 amino acids, the same building blocks that make up proteins. Scientists in Croatia created it in the early 1990s, based on part of a protein they reported finding in human stomach juice.

Almost everything known about it comes from experiments in rats and in cells, where it was studied for healing of the stomach, gut, tendons and other tissues. Those results are interesting, but many treatments that work in animals do not work in people, and very few studies have tested BPC-157 in humans.

It is not an FDA-approved medicine, and its long-term safety in people is unknown.

For students

BPC-157 (sequence GEPPPGKPADDAGLV, about 1,419.5 Da) is a synthetic pentadecapeptide. The University of Zagreb group that developed it describes it as a partial sequence of a larger "body protection compound" they isolated from human gastric juice, and they report that it is unusually stable in gastric juice. Its proline-rich N-terminal region (four prolines in the first eight residues) is one feature researchers point to when discussing that stability.

In rodent models it has been studied in gastrointestinal lesions; tendon, ligament and muscle injury; and vascular models. Proposed mechanisms include effects on the nitric oxide system and on blood-vessel growth (angiogenesis) signaling, but these come from animal and cell experiments, not people.

When you read this literature, notice three things: most papers come from one research group, sample sizes are small, and independent replication is limited. That is why VALREXA grades it Preclinical.

For researchers and instructors

Evidence base. Hundreds of publications, predominantly rodent studies from the Sikirić laboratory, using intraperitoneal, intragastric and local administration. Concentration of authorship in one group raises concerns about publication bias and the absence of independent replication.

Proposed mechanisms (preclinical). Reported interactions with the NO system (modulation of L-NAME and L-arginine effects); VEGFR2 activation and up-regulation with downstream Akt–eNOS signaling in endothelial models; activation of the FAK–paxillin pathway in tendon fibroblast migration and outgrowth; and increased growth hormone receptor expression in tendon fibroblasts in vitro. None has been confirmed in humans.

Human data. No published randomized controlled trial with clinical endpoints. Registered studies include NCT02637284 (oral safety and pharmacokinetics) and NCT07437547 (Phase 2, hamstring injury); human pharmacokinetics remain poorly characterized.

Regulatory context. Named by WADA as a prohibited non-approved substance (2022); placed by the FDA in compounding Category 2 in 2023, citing safety concerns including potential immunogenicity and peptide-related impurities; subject to FDA enforcement discretion for 503A compounding since October 2026, which is not approval. Products sold outside licensed pharmacies have unverified identity and purity.